See more : AIDITE (QINHUANGDA (301580.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Nemaura Medical Inc. (NMRD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nemaura Medical Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Atlantica Sustainable Infrastructure plc (AY) Income Statement Analysis – Financial Results
- Security National Financial Corporation (SNFCA) Income Statement Analysis – Financial Results
- Television Broadcasts Limited (TVBCY) Income Statement Analysis – Financial Results
- Precision Camshafts Limited (PRECAM.BO) Income Statement Analysis – Financial Results
- Diversified Energy Company PLC (DEC.L) Income Statement Analysis – Financial Results
Nemaura Medical Inc. (NMRD)
About Nemaura Medical Inc.
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77.04K | 503.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.55M | 344.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.48M | 159.61K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -1,916.30% | 31.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.54M | 1.56M | 1.55M | 2.01M | 2.30M | 993.83K | 1.03M | 1.03M | 824.50K | 383.86K | 658.72K |
| General & Administrative | 5.60M | 6.17M | 3.03M | 2.77M | 2.18M | 915.13K | 516.66K | 511.41K | 495.34K | 202.38K | 171.85K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.60M | 6.17M | 3.03M | 2.77M | 2.18M | 915.13K | 516.66K | 511.41K | 495.34K | 202.38K | 171.85K |
| Other Expenses | 980.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.12M | 7.73M | 4.59M | 4.78M | 4.48M | 1.91M | 1.55M | 1.54M | 1.32M | 586.23K | 830.57K |
| Cost & Expenses | 9.67M | 8.07M | 4.59M | 4.78M | 4.48M | 1.91M | 1.55M | 1.54M | 1.32M | 586.23K | 830.57K |
| Interest Income | 0.00 | 6.67M | 2.01M | 3.93K | 23.93K | 88.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.41M | 6.67M | 2.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 444.18K | 229.81K | 98.08K | 54.84K | 33.41K | 29.26K | 20.43K | 17.40K | 7.56K | 5.10K | 2.73K |
| EBITDA | -7.29M | -7.34M | -4.49M | -4.72M | -4.44M | -1.88M | -1.53M | -1.52M | -1.31M | -581.13K | -827.85K |
| EBITDA Ratio | -9,458.31% | -1,456.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.60M | -7.57M | -4.59M | -4.78M | -4.48M | -1.91M | -1.55M | -1.54M | -1.32M | -586.23K | -830.57K |
| Operating Income Ratio | -12,454.23% | -1,502.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.55M | -6.67M | -2.01M | 3.93K | 23.93K | 88.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -14.14M | -14.24M | -6.59M | -4.77M | -4.45M | -1.82M | -1.55M | -1.54M | -1.32M | -586.23K | -830.57K |
| Income Before Tax Ratio | -18,358.00% | -2,825.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -350.26K | -335.83K | -614.36K | 23.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -14.14M | -13.89M | -6.26M | -4.16M | -4.45M | -1.82M | -1.55M | -1.54M | -1.32M | -586.23K | -830.57K |
| Net Income Ratio | -18,358.00% | -2,755.83% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.57 | -0.59 | -0.28 | -0.20 | -0.25 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | -0.05 |
| EPS Diluted | -0.57 | -0.59 | -0.28 | -0.20 | -0.25 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | -0.05 |
| Weighted Avg Shares Out | 24.88M | 23.38M | 22.28M | 20.81M | 18.09M | 150.07M | 205.00M | 201.73M | 200.00M | 200.00M | 18.00M |
| Weighted Avg Shares Out (Dil) | 24.88M | 23.38M | 22.28M | 20.81M | 18.09M | 150.07M | 205.00M | 201.73M | 200.00M | 200.00M | 18.00M |
Important Update on Listing Status and Strategic Direction
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura...
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted...
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement...
Nemaura (NMRD) to Expand in UK With Metabolic Health Program
The latest program leverages Nemaura's (NMRD) world-first daily wear non-invasive CGM technology, providing individuals with real-time insights into their body's glucose dynamics.
Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
Company CEO to discuss development at 1pm EST on 15 th November 2023, at the Sidoti Virtual Investor Conference
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released...
Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.
LOUGHBOROUGH, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the appointment of Nikolai...
Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference
Loughborough, England, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will...
Nemaura Medical Provides Update on Nasdaq Compliance Status and Process
LOUGHBOROUGH, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc.(Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercialising non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today provided an update regarding the...
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
Let's be honest – penny stocks priced at less than a buck hold an irresistible appeal. Even a small investment could potentially lead to insane returns.
Source: https://incomestatements.info
Category: Stock Reports